Compare PATH & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PATH | GPCR |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.3B |
| IPO Year | 2021 | 2023 |
| Metric | PATH | GPCR |
|---|---|---|
| Price | $11.78 | $56.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 11 |
| Target Price | $14.41 | ★ $103.36 |
| AVG Volume (30 Days) | ★ 35.9M | 789.5K |
| Earning Date | 06-09-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.75 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $1,429,664,000.00 | N/A |
| Revenue This Year | $10.46 | N/A |
| Revenue Next Year | $8.66 | N/A |
| P/E Ratio | $36.20 | ★ N/A |
| Revenue Growth | ★ 9.30 | N/A |
| 52 Week Low | $9.38 | $13.24 |
| 52 Week High | $19.84 | $94.90 |
| Indicator | PATH | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 33.86 |
| Support Level | $10.19 | $18.36 |
| Resistance Level | $13.18 | $93.91 |
| Average True Range (ATR) | 0.64 | 3.48 |
| MACD | 0.21 | -0.29 |
| Stochastic Oscillator | 77.71 | 27.15 |
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.